Duke Team Addresses Barriers to Oral Chemo

Article

A streamlined nursing protocol reduced delays related to treatment with oral formulations of chemotherapy and immunotherapy, and increased patient satisfaction.

At the 43rd ONS Congress in Washington, DC, a team of nurses from the Duke Raleigh Wake-Cary Cancer Center in North Carolina will be presenting their poster, “Identifying Barriers to Oral Chemotherapy: A Nurse Qualitative Review Process to Improve Initiating Therapy, Patient Adherence, and Nurse Satisfaction.  The study authors are Katherine A. Becker, MSN, RN, OCN; Coveny Greco, BSN, RN; Ramona Basnight, MSN, RN, OCN; and Deborah H. Allen, PhD, RN, CNS, FNP-BC, AOCNP.

They will present information describing a systematic, streamlined nursing process they developed to improve the way that healthcare providers order and patients receive oral formulations of chemotherapy and immunotherapy. Their innovative protocol arose from an essential need: patients should start their treatment-especially combination therapy-in a timely manner. However, oncology nurses face multiple challenges in ensuring prompt initiation of treatment, and identification of potential procedural problems that could improve the situation falls largely on nurses’ shoulders.

As lead presenter Katherine Becker told Cancer Network, certain barriers “are delaying when patients can start their oral chemotherapy, which adds to their anxiety. For many, oral agents are their best hope for remission, and delaying the start of treatment may mean disease progression.”

The most common barrier affecting treatment includes the need for insurance preauthorization. Other obstacles include pharmacy changes and e-prescribing; financial constraints such as high copays and lack of prescription coverage; and insurance coverage denials, which can necessitate an appeals process.

Since the back-end procedures that are a prerequisite for rapid implementation of cancer treatment are handled for the most part by nursing staff, Becker and her coinvestigators set a goal of developing protocols that would increase nurses’ satisfaction and reduce their workload. This was achieved “by designating a point person [to whom] questions can be directed,” Becker explained.

The streamlined process for initiating oral chemotherapy involves a clinic nurse initiating a tailored patient-education plan upon receiving the prescription from the provider, and a triage nurse then coordinating the patient’s insurance, prescription, and medication information with a specialty pharmacy. Communication from the triage nurse back to the clinic nurse closes the loop, with detailed education calls once the medications are received, and at regular intervals during cycles of chemotherapy. Patient compliance is assessed at a scheduled clinic visit.  Becker and colleagues found that this plan reduced treatment delays and increased patient satisfaction levels.

Becker and her team emphasize in their poster that while their new SOPs did not completely eliminate the barriers that delay patients from receiving their oral therapy, they did succeed in creating “a standardized process for obtaining the medication that has led to less staff frustration, [reduced] workload, and better tracking of [patient] status for each case.”

The investigators’ future goals include an improved method of alerting nursing staff to patient medication receipt, improved patient education regarding specific treatments, implementation of a full-time dedicated oral chemotherapy nurse to manage this role, and “improved follow-up with patients once they receive their oral medication,” Becker said.

Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content